[go: up one dir, main page]

MX383090B - Composiciones y métodos para el tratamiento de enfermedades infecciosas orales. - Google Patents

Composiciones y métodos para el tratamiento de enfermedades infecciosas orales.

Info

Publication number
MX383090B
MX383090B MX2019006163A MX2019006163A MX383090B MX 383090 B MX383090 B MX 383090B MX 2019006163 A MX2019006163 A MX 2019006163A MX 2019006163 A MX2019006163 A MX 2019006163A MX 383090 B MX383090 B MX 383090B
Authority
MX
Mexico
Prior art keywords
formula
treatment
oral
infectious diseases
compositions
Prior art date
Application number
MX2019006163A
Other languages
English (en)
Other versions
MX2019006163A (es
Inventor
Mahesh Kandula
Original Assignee
Cellix Bio Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Private Ltd filed Critical Cellix Bio Private Ltd
Publication of MX2019006163A publication Critical patent/MX2019006163A/es
Publication of MX383090B publication Critical patent/MX383090B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/593—Dicarboxylic acid esters having only one carbon-to-carbon double bond
    • C07C69/60—Maleic acid esters; Fumaric acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/62—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with triarylmethyl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

La invención se refiere a los compuestos o sus polimorfos, solvatos, enantiómeros, estereoisómeros e hidratos farmacéuticos aceptables de los mismos. Las composiciones farmacéuticas que comprenden una cantidad efectiva de los compuestos de la fórmula I, fórmula II, fórmula III, fórmula IV, fórmula V, fórmula VI, fórmula VII, fórmula VIII, fórmula IX, fórmula X, fórmula Xl y fórmula XII, y los métodos para el tratamiento de enfermedades infecciosas orales, pueden formularse para administración oral, bucal, rectal, tópica, transdérmica, a través de mucosas, por losange, rocío, intravenosa, solución oral, tableta de capas por mucosa bucal, por vía parenteral, por jarabe o inyección. Estas composiciones pueden utilizarse para el tratamiento de enfermedades infecciosas orales.
MX2019006163A 2016-11-28 2017-04-19 Composiciones y métodos para el tratamiento de enfermedades infecciosas orales. MX383090B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201641040639 2016-11-28
PCT/IB2017/052244 WO2018096405A1 (en) 2016-11-28 2017-04-19 Compositions and methods for the treatment of oral infectious diseases

Publications (2)

Publication Number Publication Date
MX2019006163A MX2019006163A (es) 2019-11-28
MX383090B true MX383090B (es) 2025-03-13

Family

ID=62195419

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006163A MX383090B (es) 2016-11-28 2017-04-19 Composiciones y métodos para el tratamiento de enfermedades infecciosas orales.

Country Status (15)

Country Link
US (3) US11225463B2 (es)
EP (1) EP3538079A4 (es)
JP (1) JP2019535795A (es)
KR (1) KR20190087546A (es)
CN (1) CN110198707A (es)
AU (1) AU2017363973B2 (es)
BR (1) BR112019010809A2 (es)
CA (1) CA3044734A1 (es)
IL (1) IL266926A (es)
MX (1) MX383090B (es)
NZ (1) NZ754205A (es)
RU (1) RU2770033C2 (es)
SG (1) SG10202105113SA (es)
WO (1) WO2018096405A1 (es)
ZA (1) ZA201903572B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019119089A (ru) * 2016-11-28 2020-12-21 Целликс Био Прайвет Лимитед Композиции и способы лечения грибковых инфекций
WO2018115319A2 (en) * 2016-12-23 2018-06-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of cytochrome p450 family 7 subfamily b member 1 (cyp7b1) for use in treating diseases
JP2020109064A (ja) * 2019-01-04 2020-07-16 国立研究開発法人物質・材料研究機構 口腔バイオフィルムの内部に存在する病原性細菌の活性を低減させる方法および口腔用組成物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU557755A3 (ru) * 1968-08-19 1977-05-05 Янссен Фармасьютика Н.В. (Фирма) Способ получени производных имидазола
EG11779A (en) * 1974-11-19 1978-06-30 Janssen Pharmaceutica Nv Process for preparing of 1-(b-aryl-b-(r-oxy)-ethyl)imidazoles
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
JPS57179164A (en) * 1981-04-30 1982-11-04 Ota Seiyaku Kk Preparation of imidazole derivative
IL105200A (en) * 1993-03-29 1997-03-18 Teva Pharma Regiospecific processes for the preparation of 1, 3-bis (1, 2, 4-triazol-1-yl)-propan- 2-ol derivatives
US6407129B1 (en) * 1997-03-31 2002-06-18 Takeda Chemical Industries, Ltd. Azole compounds, their production and their use
WO2004078161A1 (en) * 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP1511490A4 (en) * 2002-05-31 2009-03-11 Transform Pharmaceuticals Inc NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS
US20070078116A1 (en) * 2003-08-20 2007-04-05 Fairfield Clinical Trials, Llc Method of treatment of otitis externa
US20050196418A1 (en) * 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CN1634064A (zh) * 2004-12-10 2005-07-06 张文芳 伊曲康唑结构化乳剂组合物及其制备方法
CN1970557A (zh) * 2005-11-25 2007-05-30 上海喜恩医药科技发展有限公司 伊曲康唑甲磺酸盐及其组合物和制备方法
US8258164B2 (en) * 2006-09-12 2012-09-04 Curatek Pharmaceuticals Holding, Inc. Nitroimidazole composition and method
US20090082363A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched posaconazole
US20140004176A1 (en) * 2010-12-29 2014-01-02 Strategic Science & Techologies Delivery of treatments transdermally for fungal infections and other indications
KR102255108B1 (ko) * 2013-03-08 2021-05-24 노파르티스 아게 활성제의 전달을 위한 지질 및 지질 조성물
ES2908827T3 (es) * 2013-12-19 2022-05-04 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
PL3227277T3 (pl) * 2014-12-05 2020-08-10 Pulmocide Limited Związek przeciwgrzybiczy
US10479776B2 (en) * 2015-05-12 2019-11-19 Lupin Limited Process for the preparation of Efinaconazole
WO2017216722A2 (en) * 2016-06-13 2017-12-21 Vyome Biosciences Pvt. Ltd. Synergistic antifungal compositions and methods thereof

Also Published As

Publication number Publication date
RU2019119103A (ru) 2020-12-21
AU2017363973B2 (en) 2022-03-03
US20220220079A1 (en) 2022-07-14
AU2017363973A1 (en) 2019-06-20
BR112019010809A2 (pt) 2019-10-01
RU2770033C2 (ru) 2022-04-14
IL266926A (en) 2019-07-31
SG10202105113SA (en) 2021-06-29
MX2019006163A (es) 2019-11-28
US11465973B2 (en) 2022-10-11
US11225463B2 (en) 2022-01-18
RU2019119103A3 (es) 2020-12-21
US20200361874A1 (en) 2020-11-19
US11649215B2 (en) 2023-05-16
EP3538079A4 (en) 2020-03-04
EP3538079A1 (en) 2019-09-18
CN110198707A (zh) 2019-09-03
WO2018096405A1 (en) 2018-05-31
CA3044734A1 (en) 2018-05-31
JP2019535795A (ja) 2019-12-12
US20220213043A1 (en) 2022-07-07
ZA201903572B (en) 2022-04-28
KR20190087546A (ko) 2019-07-24
NZ754205A (en) 2022-07-29

Similar Documents

Publication Publication Date Title
MX379545B (es) Composiciones y metodos para el tratamiento del dolor cronico.
MX386467B (es) Composiciones y métodos para el tratamiento de xerostomia (sequedad bucal)
CO2019011809A2 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
MX2018000916A (es) Derivados de benzodiazepina como inhibidores de rsv.
CY1119727T1 (el) Ενωσεις και συνθεσεις για τη θεραπεια παρασιτικων νοσων
MX384144B (es) Composiciones y métodos para el tratamiento del cáncer.
WO2013175377A3 (en) Compositions and methods for treatment of mucositis
MX2022005523A (es) Composiciones y metodos para el tratamiento de infecciones fungicas.
WO2013175376A3 (en) Compositions and methods for the treatment of local pain
CY1121063T1 (el) Αναστολεις της συνθασης της αλδοστερονης
MX382175B (es) Composiciones de profármaco de monometilfumarato
WO2014091384A3 (en) Compositions and methods for the treatment of mucositis
MX383090B (es) Composiciones y métodos para el tratamiento de enfermedades infecciosas orales.
WO2016046680A3 (en) Compositions and methods for the treatment of liver metabolic diseases
WO2014068463A3 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
MX386208B (es) Composiciones y métodos para el tratamiento de pólipos gastrointestinales.
MX386902B (es) Metodos para el tratamiento de trastornos cardiovasculares.
WO2014087323A3 (en) Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases
MX385938B (es) Nuevo derivado de catecol y composición farmacéutica que comprende el mismo.
MX2019001360A (es) Composiciones y metodos para el tratamiento de sindrome de intestino irritable.
SG10201906474QA (en) Compositions and methods for the treatment of mucositis
WO2014195850A3 (en) Compositions and methods for the treatment of neurologic diseases and neurological disorders
WO2014097137A3 (en) Compositions and methods for the treatment of seizures and neurologic diseases
WO2015028976A3 (en) Compounds and methods for the treatment of inflammatory diseases
WO2014118649A3 (en) Compositions and methods for the treatment of cardiovascular diseases